Mitochondrial plasticity in cancer-related muscle wasting: Potential approaches for its management

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 3, 2015, Pages 226-233

  Vitorino, Rui ^a   Moreira Gonçalves, Daniel ^b,c   Ferreira, Rita ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

Author keywords

cancer cachexia; mitochondrial biogenesis; mitochondrial plasticity; oxidative stress; skeletal muscle

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; BORTEZOMIB; DRONABINOL; GLUCOCORTICOID; ICOSAPENTAENOIC ACID; MEGESTROL ACETATE; MYOSTATIN ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PROTEIN INHIBITOR; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN;

APOPTOSIS; CACHEXIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; HUMAN; INSULIN RESISTANCE; MITOPHAGY; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; OXIDATIVE STRESS; PROTEIN QUALITY; REVIEW; SKELETAL MUSCLE; COMPLICATION; DISEASE MANAGEMENT; METABOLISM; MITOCHONDRION; MUSCULAR ATROPHY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; WASTING SYNDROME; WEIGHT REDUCTION;

ADENOSINE TRIPHOSPHATE; CACHEXIA; DISEASE MANAGEMENT; HUMANS; MITOCHONDRIA; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; OXIDATIVE STRESS; WASTING SYNDROME; WEIGHT LOSS;

EID: 84928474786     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000161     Document Type: Review

References (49)

1. Aapro M, Arends J, Bozzetti F, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 2014; 25:1492-1499.
2. Argiles JM, Busquets S, Stemmler B, et al. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014; 14:754-762.
3. Blum D, Stene GB, Solheim TS, et al. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model-a study based on data from an international multicentre project (epcrc-csa). Ann Oncol 2014; 25:1635-1642.
4. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10:90-99.
5. Johns N, Hatakeyama S, Stephens NA, et al. Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. PLoS One 2014; 9:e83618.
6. Onesti JK, Guttridge DC. Inflammation based regulation of cancer cachexia. Biomed Res Int 2014; 2014:168407.
7. White JP, Puppa MJ, Sato S, et al. Il-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the apcmin/+ mouse. Skelet Muscle 2012; 2:14.
8. Liu Y, Cheng H, Zhou Y, et al. Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cells. Cell Death Dis 2013; 4:e494.
9. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 2013; 6:25-39.
10. Julienne CM, Dumas JF, Goupille C, et al. Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. J Cachexia Sarcopenia Muscle 2012; 3:265-275.
11. Padrao AI, Oliveira P, Vitorino R, et al. Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity. Int J Biochem Cell Biol 2013; 45:1399-1409.
12. Antunes D, Padrao AI, Maciel E, et al. Molecular insights into mitochondrial dysfunction in cancer-related muscle wasting. Biochim Biophys Acta 2014; 1841:896-905.
13. Fermoselle C, Garcia-Arumi E, Puig-Vilanova E, et al. Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice. Exp Physiol 2013; 98:1349-1365.
14. Fontes-Oliveira CC, Busquets S, Toledo M, et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta 2013; 1830:2770-2778.
15. White JP, Baltgalvis KA, Puppa MJ, et al.Muscle oxidative capacity during il-6-dependent cancer cachexia. Am J Physiol Regul Integr Comp Physiol 2011; 300:R201-R211.
16. Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med 2011; 27:15-24.
17. Tzika AA, Fontes-Oliveira CC, Shestov AA, et al. Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int J Oncol 2013; 43:886-894.
18. Lokireddy S, Wijesoma IW, Bonala S, et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J 2012; 446:23-36.
19. Romanello V, Sandri M. Mitochondrial biogenesis and fragmentation as regulators of protein degradation in striated muscles. J Mol Cell Cardiol 2013; 55:64-72.
20. White JP, Baynes JW, Welle SL, et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the apc(min/+) mouse. PLoS One 2011; 6:e24650.
21. Iqbal S, Ostojic O, Singh K, et al. Expression of mitochondrial fission and fusion regulatory proteins in skeletal muscle during chronic use and disuse. Muscle Nerve 2013; 48:963-970.
22. Dorn GW, Kitsis RN. The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. Circ Res 2015; 116:167-182.
23. Kasahara ASL. Mitochondria: from cell death executioners to regulators of cell differentiation. Trends Cell Biol 2014; 24:761-770.
24. Nasrallah CM, Horvath TL. Mitochondrial dynamics in the central regulation of metabolism. Nat Rev Endocrinol 2014; 10:650-658.
25. Khan MM, Strack S, Wild F, et al. Role of autophagy, sqstm1, sh3glb1, and trim63 in the turnover of nicotinic acetylcholine receptors. Autophagy 2014; 10:123-136.
26. Joseph AM, Adhihetty PJ, Wawrzyniak NR, et al. Dysregulation of mitochondrial quality control processes contribute to sarcopenia in a mouse model of premature aging. PLoS One 2013; 8:e69327.
27. Remels AH, Gosker HR, Bakker J, et al. Regulation of skeletal muscle oxidative phenotype by classical nf-kappab signalling. Biochim Biophys Acta 2013; 1832:1313-1325.
28. Argiles JM, Fontes-Oliveira CC, Toledo M, et al. Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 2014; 5:279-286.
29. Aguer C, Fiehn O, Seifert EL, et al. Muscle uncoupling protein 3 overexpression mimics endurance training and reduces circulating biomarkers of incomplete beta-oxidation. FASEB J 2013; 27:4213-4225.
30. Guzman-Ruiz R, Gomez-Hurtado N, Gil-Ortega M, et al. Remodeling of energy metabolism and absence of electrophysiological changes in the heart of obese hyperleptinemic mice. New insights into the pleiotropic role of leptin. Front Endocrinol 2013; 4:175.
31. Horvath SE, Daum G. Lipids of mitochondria. Prog Lipid Res 2013; 52:590-614.
32. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013; 3:CD004310.
33. Prado CM, Sawyer MB, Ghosh S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 2013; 98:1012-1019.
34. Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 2013; 88:625-636.
35. Toledo M, Springer J, Busquets S, et al. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014; 5:315-320.
36. Yennurajalingam S, Bruera E. Role of corticosteroids for fatigue in advanced incurable cancer: is it a 'wonder drug' or 'deal with the devil'. Curr Opin Support Palliat Care 2014; 8:346-351.
37. Argiles JM, Anguera A, Stemmler B. A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. Clin Nutr 2013; 32:319-324.
38. Molfino A, Formiconi A, Rossi Fanelli F, et al. Ghrelin: from discovery to cancer cachexia therapy. Curr Opin Clin Nutr Metab Care 2014; 17:471-476.
39. Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin hcl (ono-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle 2014; 5:329-337.
40. Mueller TC, Burmeister MA, Bachmann J, et al. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol 2014; 20:9361-9373.
41. Tsubouchi H, Yanagi S, Miura A, et al. Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. Eur J Pharmacol 2014; 743:1-10.
42. Chacon-Cabrera A, Fermoselle C, Urtreger AJ, et al. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J Cell Physiol 2014; 229:1660-1672.
43. Finsterer J, Ohnsorge P. Influence of mitochondrion-toxic agents on the cardiovascular system. Regul Toxicol Pharmacol 2013; 67:434-445.
44. Argiles JM, Busquets S, Lopez-Soriano FJ, et al. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle 2012; 3:73-76.
45. Stene GB, Helbostad JL, Balstad TR, et al. Effect of physical exercise on muscle mass and strength in cancer patients during treatment-a systematic review. Crit Rev Oncol Hematol 2013; 88:573-593.
46. Maddocks M, Jones LW, Wilcock A. Immunological and hormonal effects of exercise: implications for cancer cachexia. Curr Opin Support Palliat Care 2013; 7:376-382.
47. Lira FS, Neto JC, Seelaender M. Exercise training as treatment in cancer cachexia. Appl Physiol Nutr Metab 2014; 39:679-686.
48. Donatto FF, Neves RX, Rosa FO, et al. Resistance exercise modulates lipid plasma profile and cytokine content in the adipose tissue of tumour-bearing rats. Cytokine 2013; 61:426-432.
49. Hawley JAHM, Joyner MJ, Zierath JR. Integrative biology of exercise. Cell 2014; 159:738-749.